Artiva Biotherapeutics Inc.

Artiva Biotherapeutics Inc. is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients with autoimmune diseases and cancers. Its lead product candidate, AlloNK, is an allogeneic, off-the-shelf, cryopreserved NK cell therapy designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies, driving B-cell depletion. AlloNK is being evaluated in ongoing clinical trials, including company-sponsored and investigator-initiated studies across B-cell driven autoimmune diseases such as refractory rheumatoid arthritis, Sjögren’s disease, systemic lupus erythematosus, lupus nephritis, and others. The company also advances CAR-NK programs, including AB-201 targeting human epidermal growth factor receptor 2 for solid tumors like breast, gastric, esophageal, and bladder cancers, and AB-205 targeting CD5 for hematological malignancies. Artiva Biotherapeutics Inc. operates in the healthcare sector's biotechnology industry, emphasizing accessible cell therapies for serious conditions with significant unmet needs. Incorporated in 2019 and headquartered in San Diego, California, the company leverages NK cell manufacturing technology through strategic partnerships to support its pipeline.

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Fred Aslan M.D.

Employees

106

Headquarters

San Diego, CA, United States

Website

www.artivabio.com